Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Kalaris Therapeutics, Inc.ALVR · Entity 6805 | Director · Chief Executive Officer | November 19, 2024 | November 20, 2024 |
| NEKTAR THERAPEUTICSNKTR · Entity 4364 | Director | September 23, 2026 | September 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Kalaris Therapeutics, Inc.
Report date November 19, 2024 · Filed November 20, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 723,363 |
Reported balance
After 2024-11-19 transaction · row 1
1 source rowRow 1 · 2024-11-19 · Sale · Disposed 8,706 · Balance 723,363 F1: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.545 to $0.572. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.
F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.545 to $0.572. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
NEKTAR THERAPEUTICS
Report date September 23, 2026 · Filed September 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,904 |
Reported balance
After 2026-09-23 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-23 · Grant · Acquired 2,000 · Balance 3,904 F1: Common stock was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of the Issuer's common stock. F2: This RSU award vests in full, one year following September 23, 2026. F3: On June 8, 2025, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Stock Split"). All amounts of securities listed herein have been adjusted to reflect the effect of the Reverse Stock Split. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $57.66 · Expires 2034-09-22 | Direct | 4,000 |
Reported balance
After 2026-09-23 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-09-23 · Grant · Acquired 4,000 · Balance 4,000 F4: This stock option vests in substantially equal monthly installments over the one-year period beginning on September 23, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Common stock was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of the Issuer's common stock.
F2: This RSU award vests in full, one year following September 23, 2026.
F3: On June 8, 2025, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Stock Split"). All amounts of securities listed herein have been adjusted to reflect the effect of the Reverse Stock Split.
F4: This stock option vests in substantially equal monthly installments over the one-year period beginning on September 23, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 17, 2021 Filed May 18, 2021 17:08 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | GrantStock Option (Right to Buy) · Derivative | 500,000 | $0.00 Strike: $23.74 | $0.00 |
DisclosureSEC source: 0000899243-21-019779 · doc4.xml · derivative · entry 3 Brainard Diana · CIK 0001818070 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2031-05-17 F3 · derivative.exercise_date: 25% of this option shall vest and become exercisable on May 17, 2022, with the remainder vesting in twelve quarterly installments thereafter. Read SEC document |
| May 17, 2021 Filed May 18, 2021 17:08 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | GrantCommon Stock | 170,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-019779 · doc4.xml · nonDerivative · entry 2 Brainard Diana · CIK 0001818070 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,300 F2 · shares: The shares reported in this transaction represent RSUs issued under the Plan. 25% of these RSUs shall vest on May 17, 2022, with the remainder vesting in twelve quarterly installmenters thereafter. Read SEC document |
| May 17, 2021 Filed May 18, 2021 17:08 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-019779 · doc4.xml · nonDerivative · entry 1 Brainard Diana · CIK 0001818070 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,300 F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. These RSUs shall vest in full on May 17, 2022. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 21:42 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | PurchaseCommon Stock | 6,300 | $17.00 | $107,100.00 |
DisclosureSEC source: 0000899243-20-021577 · doc4.xml · nonDerivative · entry 1 Brainard Diana · CIK 0001818070 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,300 Read SEC document |
| July 29, 2020 Filed Jul 31, 2020 18:39 UTC | Kalaris Therapeutics, Inc. ALVR · Entity 6805 | GrantStock Option (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0000899243-20-020920 · doc4.xml · derivative · entry 1 Brainard Diana · CIK 0001818070 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2030-07-29 F1 · derivative.exercise_date: This option shall vest and become exercisable in equal quarterly installments over three years, with the first installment vesting on October 29, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.